Brazilian biotechnology startup BioLinker has successfully raised $1.7 million in a new funding round to accelerate its pioneering work in synthetic biology, recombinant protein manufacturing, and artificial intelligence integration. The fresh capital infusion marks a significant milestone for the company, which was founded in 2018 by a group of scientists originating from the prestigious University of São Paulo. The investment round was spearheaded by Axcell, which contributed $1.4 million, alongside a substantial investment of approximately $240,000 provided by the São Paulo Research Foundation, known as FAPESP, through its PIPE Phase 2 program.
This financial backing arrives at a crucial juncture for BioLinker as the company prepares to scale its operations significantly. Since its inception, BioLinker has focused on developing and manufacturing high-quality recombinant proteins using advanced synthetic biology and genetic engineering techniques. These specialized products are essential for a wide array of sectors, providing foundational support for scientific research, advanced diagnostics, and various industrial applications. By leveraging genetic engineering, the company creates customized biological solutions that streamline processes for laboratories and commercial enterprises alike, positioning itself as a vital player in Brazil’s growing life sciences ecosystem.
A cornerstone of BioLinker’s upcoming expansion strategy involves the establishment of a cutting-edge, automated laboratory located at the Amazon BioBusiness Center in Manaus. This strategic geographic placement underscores the company’s commitment to tapping into the unique biological and logistical potential of the region. The new facility will heavily integrate robotics to generate vast amounts of biological data at an unprecedented scale. According to the company’s strategic roadmap, this massive influx of biological data will be utilized primarily to train sophisticated artificial intelligence models, thereby bridging the gap between advanced computational technology and biological research. Furthermore, the Manaus facility will serve as a launchpad to significantly expand DNA production capabilities within Brazil, reducing the country’s reliance on foreign synthesis and fostering domestic technological sovereignty in the biotech sector.
In tandem with its infrastructure upgrades, BioLinker is turning its focus toward substantial workforce expansion. The startup currently operates with a lean team of 12 dedicated professionals. With the new capital now secured, management plans to double its headcount, bringing the total number of employees to 24. This recruitment drive will target top-tier scientific, engineering, and operational talent to support the scaling of the automated laboratory and the ongoing development of the company’s proprietary technology stack.
Despite securing $1.7 million in this latest financing event, BioLinker’s funding round remains actively open. Company leadership is currently engaged in strategic discussions to bring an international investor on board. Bringing in a global partner is viewed as a crucial step to support the startup’s broader international expansion ambitions ahead of a much larger, planned Series A funding round anticipated within the next two years. Unlike many early-stage biotech ventures that burn through capital prior to commercialization, BioLinker already generates steady, recurring revenue from its existing product offerings. Management projects that the newly acquired capital, combined with its ongoing revenue streams, will be sufficient to fully fund three years of continuous operations, providing the enterprise with a stable runway to achieve its medium-term research and commercial milestones.
